TCOV
TEVA icon

Trust Company of Vermont’s Teva Pharmaceuticals TEVA Stock Holding History

Trust Company of Vermont’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-41
Closed -$739 – 1114
2024
Q3 		$739 Hold
41
– – ﹤0.01% 995
2024
Q2 		$666 Hold
41
– – ﹤0.01% 849
2024
Q1 		$579 Buy
+41
New +$517 ﹤0.01% 813
2021
Q3 		– Sell
-49
Closed – – 663
2021
Q2 		$0 Hold
49
– – ﹤0.01% 799
2021
Q1 		$1K Hold
49
– – ﹤0.01% 748
2020
Q4 		$0 Hold
49
– – ﹤0.01% 787
2020
Q3 		$0 Hold
49
– – ﹤0.01% 788
2020
Q2 		$1K Hold
49
– – ﹤0.01% 756
2020
Q1 		$0 Hold
49
– – ﹤0.01% 943
2019
Q4 		$0 Hold
49
– – ﹤0.01% 959
2019
Q3 		$0 Hold
49
– – ﹤0.01% 1035
2019
Q2 		$0 Hold
49
– – ﹤0.01% 1046
2019
Q1 		$1K Hold
49
– – ﹤0.01% 957
2018
Q4 		$1K Sell
49
-603
-92% -$12.4K ﹤0.01% 968
2018
Q3 		$14K Hold
652
– – ﹤0.01% 752
2018
Q2 		$16K Hold
652
– – ﹤0.01% 739
2018
Q1 		$11K Hold
652
– – ﹤0.01% 744
2017
Q4 		$12K Sell
652
-1,180
-64% -$17.8K ﹤0.01% 735
2017
Q3 		$33K Sell
1,832
-10,805
-86% -$243K ﹤0.01% 567
2017
Q2 		$420K Sell
12,637
-5,100
-29% -$158K 0.04% 237
2017
Q1 		$570K Sell
17,737
-4,497
-20% -$153K 0.06% 200
2016
Q4 		$806K Buy
22,234
+7,229
+48% +$289K 0.09% 169
2016
Q3 		$691K Buy
15,005
+1,105
+8% +$57.7K 0.09% 166
2016
Q2 		$698K Buy
13,900
+100
+0.7% +$5.32K 0.09% 159
2016
Q1 		$739K Buy
13,800
+700
+5% +$41.1K 0.1% 153
2015
Q4 		$860K Sell
13,100
-904
-6% -$55.9K 0.12% 146
2015
Q3 		$791K Sell
14,004
-60
-0.4% -$3.89K 0.12% 151
2015
Q2 		$831K Buy
14,064
+373
+3% +$23K 0.12% 154
2015
Q1 		$853K Hold
13,691
– – 0.12% 150
2014
Q4 		$788K Hold
13,691
– – 0.11% 156
2014
Q3 		$736K Sell
13,691
-277
-2% -$14.7K 0.11% 151
2014
Q2 		$732K Buy
13,968
+507
+4% +$25.9K 0.11% 151
2014
Q1 		$711K Buy
13,461
+71
+0.5% +$3.28K 0.12% 150
2013
Q4 		$537K Buy
13,390
+1,396
+12% +$55K 0.09% 160
2013
Q3 		$454K Buy
11,994
+900
+8% +$35.1K 0.08% 166
2013
Q2 		$435K Buy
+11,094
New +$432K 0.08% 158

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Trust Company of Vermont's TEVA Position: Q4 2024 in Review

Trust Company of Vermont sold out of Teva Pharmaceuticals (TEVA) in Q4 2024, closing a stake of 41 shares — an estimated $739 sold.

Trust Company of Vermont first reported a position in TEVA in Q2 2013 and held it in 36 quarters. The position peaked at $860K in Q4 2015. 584 funds tracked by Wall St. Rank hold TEVA as of Q4 2024.

  • Trust Company of Vermont reported no remaining Teva Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Trust Company of Vermont sold 41 Teva Pharmaceuticals shares in Q4 2024, an estimated $739.
  • Trust Company of Vermont first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 36 quarters.
  • Trust Company of Vermont's Teva Pharmaceuticals position peaked at $860K in Q4 2015.
  • 584 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2024.

Based on Trust Company of Vermont's 13F filing for Q4 2024, filed 15 Jan 2025.